Dipeptidyl peptidase-4 inhibitors are associated with a lower risk of osteoarthritis in patients with type 2 diabetes
Therapeutic Advances in Musculoskeletal Disease
Published online on March 30, 2026
Abstract
Therapeutic Advances in Musculoskeletal Disease, Volume 18, January-December 2026.
Background:Osteoarthritis (OA) is the most prevalent form of arthritis. Currently, no disease-modifying OA drugs are available. Increasing interest has focused on repurposing antidiabetic medications to prevent OA. Preclinical studies showed that ...
Background:Osteoarthritis (OA) is the most prevalent form of arthritis. Currently, no disease-modifying OA drugs are available. Increasing interest has focused on repurposing antidiabetic medications to prevent OA. Preclinical studies showed that ...